AVTX (STOCKS)
Avalo Therapeutics, Inc. Common Stock
$13.340000
-0.320000 (-2.34%)
Prev close: $13.660000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Garry Arthur Neil
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $303.09M
- Employees
- 23
- P/E (TTM)
- -2.24
- P/B (TTM)
- 3.05
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $59.00K |
| Benefits Costs and Expenses | $78.15M |
| Costs And Expenses | $72.98M |
| Nonoperating Income/Loss | -$5.17M |
| Operating Expenses | $72.98M |
| Operating Income/Loss | -$72.93M |
| Income/Loss From Continuing Operations After Tax | -$78.26M |
| Income/Loss From Continuing Operations Before Tax | -$78.09M |
| Income Tax Expense/Benefit | $165.00K |
| Income Tax Expense/Benefit, Current | $0.00 |
| Income Tax Expense/Benefit, Deferred | $165.00K |
| Net Income/Loss | -$78.26M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$78.26M |
| Net Income/Loss Available To Common Stockholders, Basic | -$78.26M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.84 |
| Diluted Earnings Per Share | -$5.84 |
| Basic Average Shares | 13,404,830 |
| Diluted Average Shares | 13,404,830 |
| Assets | $116.46M |
| Current Assets | $105.29M |
| Cash | $98.30M |
| Other Current Assets | $6.99M |
| Noncurrent Assets | $11.17M |
| Liabilities | $33.41M |
| Current Liabilities | $12.94M |
| Accounts Payable | $137.00K |
| Wages | $4.13M |
| Other Current Liabilities | $8.67M |
| Noncurrent Liabilities | $20.47M |
| Equity | $83.05M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $83.05M |
| Temporary Equity | $0.00 |
| Temporary Equity Attributable To Parent | $0.00 |
| Liabilities And Equity | $116.46M |
| Net Cash Flow From Operating Activities | -$51.46M |
| Net Cash Flow From Operating Activities, Continuing | -$51.46M |
| Net Cash Flow From Investing Activities | -$81.72M |
| Net Cash Flow From Investing Activities, Continuing | -$81.72M |
| Net Cash Flow From Financing Activities | $14.59M |
| Net Cash Flow From Financing Activities, Continuing | $14.59M |
| Net Cash Flow | -$118.59M |
| Net Cash Flow, Continuing | -$118.59M |
| Comprehensive Income/Loss | -$78.19M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$78.19M |
| Other Comprehensive Income/Loss | -$78.19M |